Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to discern whether supplementation of Antithrombin III will
decrease coagulation and inflammation associated with cardiopulmonary bypass in infants
undergoing cardiac surgery.